HVCN1 and breast carcinoma: Consistently, a pharmacological HV1 inhibition was previously shown to compromise the viability of various cell types including Jurkat T lymphocytes (20), chorion-derived mesenchymal stem cells (14), activated mouse microglia (23), myeloid-derived suppressor cells (9), breast cancer (25) and glioblastoma multiforme cell lines (38).